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Abstract
Delivery agents which can carry the {Ru(NO)}e chromophore (" caged NO ") are desired for
vasodilation and for photodynamic therapy of tumors. Toward these goals, complexes derived from
[RuCla(NO)(HO)] (1) have been prepared using dipyridylamine (dpaH) as mono and bis adducts,
[Ru(NO)Cl(dpaH)] (2) and [Ru(NO)CI(dpaH)]CI (3). The dpaH ligands coordinate cis to the
Ru(NO) axis.The mono derivative is a model for a potential DNA groove-spanning binuclear complex
{[Ru(NO)Cl](tpada)} (4) which has two DNA-coordinating Ru centers, photo-labile {Ru(NO)}e
sites, and a groove-spanning tether moiety.The binuclear assembly is prepared from the tethered
dipyridylamine ligand N,N,N’,N’-tetrakis(2-pyridylmethyl)adipamide (tpada) which has recently been
shown to provide a binuclear carrier complex suited to transporting Ru and Pd agents. A related
complex, [Ru(NO)Cl(pida)] (5) with the {Ru(NO)}e moiety bound to (2-pyridylmethyl)iminodiacetate
(pida) is also characterized as a potential "caged NO" carrier. Structural information concerning the
placement of the pyridyl donor groups relative to the {Ru(NO)}e unit has been obtained from H and
C NMR and infrared methods, noting that a pyridyl donor trans to NO causes "trans strengthening"
of this ligand for [Ru(NO)Cl(pida)], whereas placement of pyridyl groups cis to NO causes a
weakening of the N-O bond and a lower NO stretching frequency in the dpa-based complexes.
Introduction
The complex [RuCla(NO)(HO)] (1) has been studied by Bettache, Carter et al. as a source
of "caged NO ", a reagent suited to vasodilation and photodynamic therapy [1,2]. Other photo-
releasing systems for NO dissociation have been reviewed [3,4]. The quantum yield for photolysis of
(1) is low (q 0.012] [1], requiring the development of other ligand donors that can enhance the
photo-dissociation chemistry in order to have a viable agent for photodynamic therapy. Additionally,
the biodistribution of (1) has not been studied. Information on what physiologically accessible
donors bind to the {Ru(NO)}e core have been unavailable except for the report of enhanced
electrophoretic mobility in the presence of glycine or alanine [5]. RuCl(NO)-derived species are also
reported to be the ones involved in the transport of radioactive eRu into fish and other aquatic
species [5].
Well characterized complexes derived from RuCla(NO) have only been reported in 1999. A
tridentate methionine complex [Ru(NO)Cl(methionine)] complex that has been characterized by X-
ray diffraction [6]. Only recently have the complexes of (1) with imidazole at 1, 2 and 3 ratio
of {Ru(NO)}e imidazole, and complexes with histidine and histamine been reported [7]. The
main species of these imidazole, histidine and histamine complexes are as shown in drawings -5 o n
the next page. Imidazole addition occurs cis to the NO moiety at and 2, followed by trans
addition at 1:3. However, histidine addition at has the imidazole donor trans to NO due to an
electrostatic steering from the anionic carboxylate to NO that directs the imidazole donor in the
trans location. The histamine complex follows the cis addition of imidazole since it lacks a
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In another current report from our research group [8], we have described the coordination of
the {Ru(NO)}e unit to the peptides (gly-gly-gly-2H) and (gly-gly-his-2H) wherein the peptide adopts a
planar coordination with an axial {Ru(NO)} group. Attachment is via the terminal amino donor, two
peptido ionized N donors and CI for (gly-gly-gly-2H) or the imidazole donor for (gly-gly-his-2H) [8].
The behavior of the {Ru(NO)}a+ unit toward peptide coordiation is the same as the well-characterized
square-planar analogues of Pd, Pt and Ni, except that the {Ru(NO)}+ complexes have the axial
NO and CI or HO donors, whereas the Ni, Pd, Pt family are strictly square-planar.
The present paper describes stable complexes that can be obtained using pyridyl-based
donors for the {Ru(NO)}e core. Godwin and Meyer have prepared a his bipyridine complex,
[Ru(NO)Cl(bpy)]/, which by virtue of steric constraints from the two bpy ligands cannot retain the
four pyridyl donors in the plane cis to NO [9]. A pseudo-square planar arrangement of ligands has an
appea-I for the development of carrier complexes of NO that might associate with DNA by intercalation
as a means of bringing "caged NO" into the environment of DNA. Photolysis of such bound "caged
NO" species could then be used to induce local DNA cleavage. Our efforts in this regard have
involved the use of the dipyridylamine (dpaH)ligand, which due to the central nitrogen linkage,
affords a flexible donor that avoids the steric problems associated with two bipyridines. Indeed, it is
reported herein that and 2 complexes with dpaH are obtained with ligands cis to NO+.
An extension of the simple dipyridylamine donor in which two dipyridylamine moieties are
linked by an adipyl chain forming the recently prepared ligand tpada [10], has been carried out to
incorporate two RuCI3(NO) headgroups that are bound by tpada. This arrangement affords a "caged
NO" binuclear complex that in principal can span the major groove of DNA, form local coordination
adducts by nucleobase displacement of CI, and can stand ready for the photo-release of NO.
Lastly, the present paper describes the coordination of the pyridyl-aminocarboxylate hybrid
ligand (2-pyridylmethyl)iminodiacetate, (pida). NMR evidence indicates a major product
[Ru(NO)Cl(pida)] with the pyridyl donor trans to NO+. Such modifications in which the donor
properties of the group trans to NO+ has promise as a route to enhancement of the photo-lability of
the NO chromophore. The {Ru(NO)Cl(pida)] complex may be one of a series of trans-modified,
"caged NO" complexes of use to photodynamic therapy.
Materials and Methods
Reagents: [RuCI3(NO)(H20)2 was prepared by the method of Fletcher et al. [11] from RuCI3(H20)3
(Aldrich). 2,2’-dipyridylamine was also used as supplied by Aldrich. (2-pyridylmethyl)iminodiacetic
acid (Hpida) synthesized for a former study of the [Fe(NO)(pida)] [12] and used from that supply.
N,N,N’N’-tetrakis(2-pyridyl)adipamide (tpada)was synthesized as described in a recent publication
[10]. All other reagents were analytical grade. Water was distilled deionized water from a house
supply.
Instrumentation: H and 3C NMR spectra were recorded on a 300 AC Bruker NMR spectrometer.
Solid samples were dissolved in DO (Aldrich) and calibrated against the 4.80 ppm HOD resonance
line. pD adjustments were made using NaOD or DCl. aC NMR spectra were calibrated against p-
dioxane (66.6 ppm)in the proton decoupled mode. Signals were averaged for 3C NMR for a
minimium of 8 h. Typical techniques matched those of recent prior publications on N-heterocyclic
and NO complexes of [Ru(hedta)] [13-15]. UV-visible spectra were recorded on a Varian-Cary
118C scanning spectrophotometer using 1.00 and 0.100 cm quartz cells, and maintaining the
concentrations of the complexes in the range of 1.00xl0
3 to 2.00xl0M by weighing out samples
on an analytical balance and dissolving the solids in volumetric flasks. Infrared spectra were obtained
in the FTIR mode on a ATI Mattson Genesis Series FTIR. Samples were prepared as KBr pellets,
pressed at nine tons.
[Ru(NO)CIs(dpaH)] (2) and [Ru(NO)CI(dpaH_)]CI (3) samples 0.2507 g (1.06x10Smol)
RuCI3(NO)(HO) and 0.1779 g dpaH (1.04x10 mol) were weighed into a 50 mL round-bottom flask
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containing a rice sized stirring bar. The flask was sealed with a septum, and then purged with N
through a syringe needle inlet and exit for 15 min. This was necessary to prevent a catalyzed
oxidation of dpaH as determined from a trial without N purging. 25.0 mLof N-purged HO was added
by a syringe. The sample flask was heated for 2h at near boiling on a water bath while magnetic
stirring was achieved. The solution’s color changed from purple of (1) to a brownish-orange product.
A small amount of undissolved dpaH was removed by filtration. The sample was concentrated by
rotary evaporation at 45C. A light tan solid formed and was isolated, washed with cold HO and
ethanol, and dried in a vacuum desiccator with pumping overnight. The procedure was repeated for
the "2 complex, isolated as [Ru(NO)CI(dpaH)]CI by combining 0.2081 g (8.76x10
.4 mol of (1) and
0.3454 g of dpaH (2.02x10 mol) in 35 mL of N-purged water in an N-purged round-bottom flask.
The sample cycle included heating for 2h, removal of a trace of unreacted dpaH by filtration, and
concentration of the filtrate at 45C under reduced pressure, followed by drying in the desiccator
under vacuum. NMR and IR methods described in the main text establish that the products have
high puity, and are absent of unreacted (1) or free d.paH.
{[RuCl(NO)](tpada)} (4)" 0.080 g of (1) (3.37x10-
mol) and 0.078 g (1.72x10
4 mol) of tpada were
combined in an empty 50 mL round-bottom flask. After N purging of the flask, 20.0 mL of N-purged
deionized water was added by syringe. The flask was heated on a water bath to near boiling for 4.5 h.
At the end of this period, there was a small amount of unreacted tpada still visible. The solution color
was brownish-orange. The solution was allowed to stir overnight. At that point, a yellowish-brown
solid was obtained upon concentration in a rotary evaporator at 45C under reduced pressure. The
final product upon drying had a shiny brown appearance. NMR data showed the absence of
unreacted free ligand or the presence of any significant amount of a adduct that would lower the
symmetry of protons along the tether chain. IR data show an absence of unreacted (1). Thus, a
sample of high purity for a binuclear product is indicated.
[Ru(NO)Cl(pida)] (5) 0.1518 g of (1) (6.39x10
4 mol) and 0.1425 g of Hpida (6.36x10
4 mol) were
placed in a 50 mL round-bottom flask with a stir bar, sealed and purged with N fo_r 15 min, and 30.0
mL of N-purged deionized water was added. The solution was heated at 55 to 60C for 3 h while the
solution color slowly changed from the purple of (1) to an orange color of the product. This solution
was rotary evaporated to a solid and dried under vacuum in a desiccator. NMR indicated a high purity
without the presence of unreacted Hpida ligand.
Results
1 1 and 1 2 dpaH complexes (2) and (3) prepared from (1)
2,2’-dipyridylamine in DO or acidified by DCI show three resonances that integrate 2
for the protons. The numbering scheme for the dpaH ligand is given at the top of the next page in a
drawing 6 of dpaH. These are are assigned to the H-6,6’ pair at 8.30 ppm (indistinguishable doublet),
H-4,4’ pair at 8.00 ppm (triplet splitting), and an overlapped multiplet at 7.20 ppm for the composite
resonances of the H-3,3’ and H-5,5’ hydrogens.
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Upon coordination in the [Ru(NO)Cl(dpaH)] product (2), all four protons are differentiated
and shifted relative to the free ligand. The H-6,6’ pair moves upfield to 8.18 ppm (singlet) H-4,4’
moves upfield to 7.76 ppm (triplet) while H-3,3’ moves downfield to 7.27 ppm (doublet) and H-5,5’
shifts upfield to 7.03 ppm as an unresolved singlet. The presence of four resonances indicates the
non-lability of the coordinated dpaH in contrast to the observations of lability for coordinated
imidazole donors [7]. Also, there is only one set of ligand resonances which affirm that the pyridyl
donors of dpaH must be placed symmetrically, and hence, cis to NO+, in the [Ru(NO)Cl(dpaH)]
complex. There was no detectable change in the H NMR spectrum with time for over several days,
which rules out a facile isomerization in the coordination mode of dpaH in the complex. Therefore the
CI ligands occupy the fac positions in the 1:1 dpaH complex, and the dpaH ligand does not readily
dissociate.
The presence of the nitrosyl group is confirmed by the FT-IR spectrum, showingo at 850
cm. The significance of this value in confirming a cis-coordinated dpaH ligand will be discussed later.
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The UV-visible spectrum exhibits a band at 430 nm with an of 61 Mcm, comparable with similar
complexes such as [Ru(NO)Cl(cyclam)](PF6) (Xrax 435 nm, s 54 M cm) [16].
The 13C NMR spectra confirm the 1H NMR results, establishing coordination of dpaH as a
bidentate donor. In the free ligand dpaH, the carbon resonances appear at 150.75 ppm for C-2,2’,
113.96 ppm for C-3,3’, 140.40 ppm for C-4,4’, 118.14 for C-5,5’ and 142.33 ppm for C-6,6’. In the
isolated complex, [Ru(NO)CI3(dpaH)] these resonances remain pairwise equivalent, and are shifted
1.00 ppm downfield for C-2,2’ to 151.75 ppm and 1.03 ppm downfield for C-4,4’ at 141.43 ppm. The
other carbons shift upfield C-6,6’ to 141.92 ppm (a-0.41 shift), C-5,5’ at 117.81 (a -0.33 ppm shift)
and C-3,3’ at 113.74 (a -0.22ppm shift). It is noted here that a protonation equilibrium would cause a
downfield shift for C-6,6’ rather than the observed upfield shift due to the combined influence of the
Ru(CI3(NO moiety. That the C-2,2’ and C-6,6’ resonances are the most strongly affected is another
indicator of coordination. The equivalence of the pyridyl rings again requires that one of the rings
cannot occupy the position trans to NO+ as this would differentiate the rings.
The complex that is isolated at 2 {Ru(NO)}6 dpaH stoichiometry yielded a nitrosyl
stretching frequency of 1850 cm. The UV-visible spectrum is nearly the same as for the
complex except that the absorbance maximum is shifted by 5 nm to 435 nm, and the extinction
coefficient is modestly higher at 86 Mcm. The 1H NMR spectrum of [Ru(NO)Cl(dpaH)]+ (3) in DO
has slightly different shifts than for the complex. However, the important feature is that all four
pyridyl donors retain equivalency, requiring that both dpaH ligands are coordinated cis to NO and
trans to each other. H-6,6’ appears at 8.19 ppm as a singlet (only 0.01 ppm downfield of the
complex), the triplet for H-4,4’ appears at 7.87 (0.11 ppm downfield of the "1 complex), H-3,3’ at
7.22 as an unresolved singlet 0.05ppm upfield of the complex and H-5,5’ at 7.11ppm, again
upfield of the "1 complex. Thus, the detection of two resonances downfield and two resonances
upfield of those for the complex distinguish the 2 complex as a distinct entity inspite of the
identical to value and very similar UV-visible spectra for the and 2 complexes. Since the
origin of the band near 430 nm is considered to be a spin-forbidden d-d transition (A ---> 3-1") along
with partial MLCT mixing of the Ru ---> NO charge transfer [16], it is not surprising that trading cis
ligands to the {Ru(NO)}
6 unit will produce very modest changes in the spectral maximum or probability
of the transition. Thus, the net ligand field from cis donors of two CI plus a dpaH ligand may not be so
different from two cis dpaH ligands, whereas changing the ligand trans to NO would produce a more
dramatic change in the visible transition energy.
The 13C NMR spectrum of the [Ru(NO)Cl(dpaH)]Cl complex (3) again shows the C-2,2’
carbon resonances as the most downfield, shifted 1.64 ppm to 152.39 ppm. The C-4,4’ resonance
shifts 140.76 ppm (0.36 ppm downfield of the free dpaH ligand), a lesser shift than for the
complex, but in the same electronic sense. The C-6,6’ resonances appear upfield at 140.50 ppm,
shifted by 1.17 ppm downfield for the 2 complex instead of an upfield -0.41 ppm shift for the
complex. The origin of this difference is either the differing influence of trans CI donors in the
complex vs. the trans N donors in the 1:2 complex, or it reflects the flexing motion of the dpaH rings
that must occur to produce four NMR-equivalent pyridyl rings in the 2 complex. Models show that
the H-6,6’ and C-6,6’ atoms may stay below the plane, away from the {Ru(NO)}e moiety. But in the 1
2 complex, each H-6,6’ proton and their C-6,6’ carbons must spend half of their time above the RuN4
plane. This places the H-6,6’ and C-6,6’ atoms above the axial current in the NO+ triple bond a
greatly different environment than for the complex where the dpaH ligand con maintain these
same atoms away from the {Ru(NO)} unit for a much higher percentage of the time. This gives added
evidence for the distinct identies of the and 2 complexes. As for the "1 complex, the more
electronically remote C-3,3’ and C-5,5’ resonances move upfield to 113.54 (a-0.42 ppm shift vs.
free L) for C-3,3’ and to 117.71 (-0.43 ppm) for C-5,5’ carbons. These are only slightly different from
the respective -0.22 ppm and -0.33 ppm shifts for the complex’s resonances in the same
position. Thus, the large reversal for the C-6,6’ pair is clear evidence for a unique 2, eg.
[Ru(NO)CI(dpaH)]
/ species vs. the [RuCl(NO)(dpaH)] complex.
tpada binuclear complex (4) prepared from two equivalents of (1)
The H NMR spectrum of tpada exhibits a doublet at 8.56 ppm for the H-6,6’ pair, a triplet at
8.22 ppm for the H-4,4’ pair a triplet at 7.69 ppm for H-3,3’ and a doublet at 7.36 for the H-5,5’ pair
and methylene CH=’s at 2.22 ppm for the CH’s nearer the amide linkage of the dipyridylamine
headgroups and 1.52 ppm for the inner pair of CH’s in the tether chain. The numbering for the
tpapda ligand is shown by drawing 7:
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Upon coordination to the RuCl3(NO) moiety at each end of the tpada ligand, one obtains a 1H
NMR spectrum showing differentiated H-6 and H-6’ protons with singlet resonances at 8.43 and
8.27 ppm. H-4,4’ appear as an equivalent singlet at 8.01 ppm, H-3,3’ has shifted upfield to 7.47 ppm
along with H-5,5’ to 7.23 ppm. All peaks are rather sharp singlets, but these have lost resolution of
their couplings across the ring upon metallation. The tether protons experience downfield shifts to
2.38 ppm for the CH2’s adjacent to the amide linkage and to 1.60 ppm for the interior CH2’s, relatively
small shifts as expected by the increasingly remote positions from the RuCI(NO) headgroups. The
resonance at 2.38 ppm of the CH2’s that are adjacent to the amide linkage are split into a doublet-of-
doublets pattern, indicative of a loss of free rotation at this position. This is logically explained by the
bulky [RuCla(NO)(dpa-R)] headgroup that cannot easily rotate in space with motions that randomize
orientations as easily as in the free ligand tpada. Allowing for the =-conjugation that extends from the
ruthenated pyridyl donors through the amide linkage all attempting to retain planarity to maximize
the amido bonding in the carbonyl region-- provides differentiation of the CH2protons which stay
fixed in space relative to the orientation of the {Ru(NO)} axis.
This same -conjugation around the amide carbonyl establishes planarity of the carbonyl unit
together with the pyridyl ring planes. As a consequence, the two pyridyl rings of tpada are not
equivalent upon coordination, whereas the simple dpaH ligand without extended =-conjugation to a
carbonyl at the central amine retains an equivalency of the coordinated pyridyl rings on a dpaH ligand
as discussed for the [RuCl3(NO)(dpaH)] complex in a prior section of this paper. The C NMR spectra
for free tpada and coordinated tpada of the 2 RuCI(NO) tpada complex exhibit the anticipated
changes upon coordination, retaining equivalency for positions, even those differentiated by H
NMR methods. A spectrum of the 2 complex and the free ligand could not be directly compared.
The solubility of free tpada is very low. In order to obtain a sufficiently high concentration that would
allow forC data collection, we had to protonate the tpada as H2tpada2/. In this species the protons
are not equivalently shared by the pyridyl N donors, causing inequivalency of all but the C-2,2’
carbons. Upon coordination, the equal donation of each N-donor of the bidentate headgroup of
tpada toward RuCI(NO) restores the equivalency of the pairwise assignments for the two pyridyl
rings. Thus, the H-6,6’ protons are more sensitive to differences within the whole complex,
stemming from the electronic withdrawing effect and the nearness to the =-conjugation of the amide
system than are the pyridyl ring carbons whose energies are dominated by their position within the
pyridyi =-cloud rather than peripheral electron densities. The location of the chemical shifts for the
ring carbons in the {[RuCl(NO)]2(tpada)} complex are in general upfield by ca. ppm of those of the
protonated H2tpada
2+ species.
The infrared spectra of the tpada ligand and its 2:1 complex reveal added features
concerning coordination. The nitrosyl stretching frequency is at 1872 cm in {[RuCl(NO)]2(tpada)}
compared to 1850 cm in [RuCla(NO)(dpaH)], indicative of the fact that the withdrawing amido
functionality of tpada allows for weakened back-donation of the Ru center to coordinated NO+. The
free tpada with back-donation from Ru into the pyridyl ring- amido assembly has weakened carbonyl
bonds as exhibited by amide stretches at 1655 and 1604 cm in the complex compared to the
stronger carbonyl bonds with strettches at 1679 and 1585 cm in the starting tpada ligand.
[Ru(NO)Cl(pida)] Complex (5)
The H NMR spectrum of the free ligand pida
2 and its complexes derived from (1) are shown
in figure 1A and 1B, repectively. The ligand resonances are defined on the figure. The CH2’s of the
glycinato arms appear as a singlet, being freely rotating groups in D20 solution. Ring protons for H-6
is an anticipated doublet at 8.60 ppm, H-4 is a multiplet at 7.91 ppm and overlapped H-3 and H-5
protons resonating from 7.46 to 7.61ppm.There are several isomers in the aboundance of 64%,
36% and ca. 1% formed when pida
2" coordinates to (1). These are identified as isomers A, B and C in
the figure.
71Vol. 7, No. 2, 2000 Developing Carrier Complexesfor "CagedNO RuCI3(NO)(H20)2
Complexes ofDipyridylamine, (dpaH)
The major isomer A has resonances at 8.71 ppm (doublet) for H-6, 8.25 ppm (multiplet) for H-
4 and 7.86 ppm for the H-3, H-5 pair. The (CH)py protons are present in a coordinated chelate as
shown by the AB pattern at 5.38 and 5.03 ppm (J 15.8 Hz). Two equivalent CHCO methylenes
have another AB pattern at 4.65 forH and 4.44 ppm for H. This requires carboxylate chelation and
O+
CIRtIO
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a symmetrical placement of those donors. This defines the structure as shown here in 8 for isomer
A.
Further evidence for this structure of the dominant species was obtained from a 1676 cm
carboxylate stretch indicating coordinated carboxylates) and a nitrosyl st,retching frequency of 889
cm.This o value requires the influence of a "trans strengthening’ axial donor as has been
described in the literature [17 20]. From this, we infer that the pyridyl donor of pida is trans to NO*
in isomer A, consistent with the placement of the two carboxylate donors at "in-plane" equivalent
locations as in 8 above. Since the sample is a mixture of 64% isomer A and 36% isomer B in which a
component to the band would appear near 1871 cm for isomer B’s contribut’ion, the true nitrosyl
stretching frequency for isomer A is calculated as 1898 cm from weighted averages.
The lesser isomer B has the H-6 resonance at 8.88 ppm (doublet), H-4 at 8.33 ppm
(multiplet, and the H-3, H-5 pair at 7.88 and 7.70 ppm. An AB pattern for the lesser isomer’s (CH)py
features are located at 4.56 ppm and > 4.69 ppm, the latter being hidden by the HOD resonance. A
singlet of area matching the corrected integration of the (CH)py group is found for isomer B at 3.78
ppm as a singlet. This implies a pendant glycinato arm. Since there are no other resonances that
integrate for the remaining glycinato functionality, we are forced to assume that it is coordinated and
buried by the HOD resonance as would be expected for a more downfield resonance, caused by
less cancellation of charge at the Ru center because of a pendant carboxylate. The differences in
the pyridyl region from the trans donor in isomer A implicates that the pyridyl group is placed cis to
NO* in isomer B as shown in drawing 9. In the earlier estimation of the nitrosyl stretching frequency
for isomer A, we assumed a value for X)o close to 1871 cm, the value for the
[RuCl(NO)(imidazole)(HO)] complex wherein the one N-heterocyclic donor is cis to NO* [7].
The very low abundance isomer C has pyridyl resonances at about 8.22 ppm, from 8.25 to 8.33 and
as a shoulder on the more major isomers at 7.69 ppm. There are no simple singlets for pendant
carboxylates and the locations of the coordinated CHCO resonances for C will be split beyond
detection under the more major resonances. We conclude that isomer C is most probably one in
which the pendant carboxylate of isomer B has displaced a CI and is bound as in drawing 10 in any
event, the amount of isomer C is very small. We have included it for completeness, and because its
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presence is required to account for accurate integration areas for some of the CH and pyridyl
resonances of isomers A and B.
All of the observations reported from the H NMR and infrared data are confimed by the laC
NMR data on (.5). In the free ligand aC NMR spectrum of the parent pida ion, the carboxylate
carbons resonate at 170.46 ppm. The methylene region shows one resonance at 58.82 ppm of
twice the intensity of another at 56.88 ppm. These are assigned to the glycinato methylenes and the
pyridyl arm methylene, respectively. Upon coordination of pida to (1), the C NMR spectrum shows
multiple sets for each C resonance that support the presence of the three isomers (A, B, C) as
discussed above from H NMR assignments. Some of the coordinated resonances are shifted as
much as 17 ppm. Three types of carboxylate carbons, two coordinated with shifts of 181.55
(downfield by + 11.10 ppm of the free L) and 179.81 ppm (downfield by +9.36 ppm) appear for
isomers A and B, respectively. A resonance for the pendant carboxylate of isomer B is at 174.02
ppm. Resonance for the isomer at 1% abundance according to the H NMR results are too weak for
carbonyl carbons for detection.
The carbons in the pyridyl ring are shown with shifted resonances in two separate sets for
isomers A and B. Since these protons have a C-H bond and give greater intensity than for carbonyl
carbons, even the 1% isomer C is detected slightly above the baseline noise. The major isomer A
has resonances at 159.94 ppm (downfield by +10.47 ppm of the free L) for C-2, at 152.64 ppm
(downfield by +9.36 ppm) for C-6, at 145.11 (downfield by +6.37 ppm) for C-4, at 142.41 ppm for C-
3 (downfield by +17.08 ppm) and at 125.81 (downfield by +0.87 ppm) for C-5.
Supporting the presence of a second isomer B are the pyridyl resonances at 160.91 ppm
(+11.44 ppm downfield) for C-2, at 151.29 ppm (+2.26 ppm downfield) for C-6, at 143.35 ppm (+
4.61 ppm downfield) for C-4, at 127.45 ppm (+2.12 ppm downfield) for C-3 and at 125.52 (+0.58
ppm downfield) for C-5. The methylene carbons also exhibit downfield shifts as a a result of
coordination. These are identified by five resonances, indicative of two isomers-- one with equivalent
glycinato arms and apyridyl methylene, and another with three different methylenes which requires
one coordinated carboxylate and one pendant carboxylate and the associated pyridyl methylene.
The equivalent glycinato methylenes for isomer A resonate at 73.48 ppm (downfield by +
14.66 ppm of the free L). The matching pyridyl methylene is detected at 65.89 ppm (downfield by
+9.02 ppm). Those for isomer B are detected at 70.02 ppm (downfield by +11.20 ppm) for the
coordinated glycinato arm, at 55.98 ppm (upfield by 2.84 ppm) for the pendant glycinato arm and at
56.13 ppm (upfie/d by -0.74 ppm) for the pyridyl methylene of isomer B.
Discussion
The H and 1C NMR data for [RuCI3(NO)(dpaH)] (2) establish the coordination and non-
lability of the dpaH ligand in this complex. The nitrosyl stretching frequency at 1850 cm, below the
1895 cm stretch for (1), shows that coordination produces a weakening of the NO stretching
frequency, rather than the "trans strengthening" when a stronger donor than CI is trans to NO [17-
22]. This confirms the "in-plane" coordination of dpaH, the fac placement of the three CI donors,
and the NMR equivalency of the two pyridyl donors.
When the second dpaH ligand is added to (2) forming [Ru(NO)CI(dpaH)]CI (3) in the
isolated solid, both dpaH ligands are retained in the plane cis to NO as shown by ’the NMR
equvalency of the four pyridyl donors, and the absence of change in theo value (again 1850 cm
for the bis complex). By contrast, the bis bipyridine complex of seeming identical inner-sphere
coordination with bpy replacing dpaH, [Ru(NO)Cl(bpy)]+, exhibits the nitrosyl stretch at 1931 cm.
This is an example of the "trans strengthening" effect as one of th pyridyl dopors of bipyridine must
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be placed in the axial site trans to NO+ in order to avoid steric contacts that occur for two in-plane bpy
ligands. The flexibility of the dpaH ligand around the central amine NH affords adjustability in the case
of dpaH, such that two in-plane donors can coordinate, yet avoid the steric difficulties of the more
planar bpy system. Models have been built which clearly show that a flexing motion can be achieved
that place the H-6,6’ hydrogens of each dpaH ring set in (3) above the RuN4 plane and close to NO+
for 50 percent of the time, while the alternate dpaH donor projects its H-6,6’ set below the RuN4
plane. The flexing motion of the rings allows for equilibration of the two configurations, and hence
NMR equivalency.
The very similar UV-visible electronic spectra for comp!ex (1), (2) and (3) emphasizes the fact
that the observed electronic transition near 430 nm and 435 nm for (2) and (3), respectively, like
those in the cyclam analogue of (3) [16], are Ru to NO MLCT transitions in character admixed with a
d-d component. The dominance of the MLCT nature accounts for extinction coefficients above 0
Mlcm and the relative insensitivity to the cis in-plane donors.
The formation of the binuclear complex {[RuCl(NO)](tpada)} (4) shows that a more
competitive :-acceptor ligand in the in-plane position can effectively compete with NO for back-
donation. In doing this, the back-donation to NO decreases and the nitrosyl stretching frequency
increases from the 1850 cm value with one dpaH ligand in (2) to the observed value of 1872 cm-
in
(4). The effect is not large enough to achieve values above 1895 cm that would be characteristic of
a trans placement of one pyridyl donor. Hence, the coordination of the tpada headgroup in the
binuclear complex (4) is still in the cis-to-NO arrangement as in the simple dpaH complex (2). The
present study has shown that it is possible to prepare a binuclear tethered "caged NO reagent that
is structurally capable of spanning the major groove of DNA and afford covalent bond formation by
displacement of a CI donor at the Ru center. Solubility difficulties with the binuclear complex (4)
cause this complex, itself, to have limited potential use. It is desirable to prepare {Ru(NO)}6-chelated
and tethered complexes wherein the chelating site is a -donor rather than the =-acceptor
competitor ligand as in tpada. However, the binuclear complex (4) is important as a working model for
the design of better antitumor metallodrugs that carry forth the present theme. The better :-
donating peptido complex of {Ru(NO)}e derived from (gly-gly-gly-2H) [8] hold high promise in this
regard, combining bio-compatibility of the ligand with ones that can be incorporated with more
soluble spacer ligand components via rather common synthetic strategies.
The [Ru(NO)Cl(pida)] complex (5) occurs as several isomers. The major isomer (64%) has
the pyridyl donor in the position trans to NO+, causing a trans strengthening of the nitrosyl stretch at
a calculated value of 1898 cm. An alternate placement of the pyridyl donor at an in-plane position cis
to NO occurs 36 % of the time. In this .arrangement, strain and the less good trade of an axial
carboxylate for CI than a pyridyl donor for CI prompts a pendant carboxylate instead of the full
quaternary donation available from pida that is displayed in the major isomer. In a prior study with the
more simple N-methyliminodiacetate ligand (mida) that lacks the pyridyl donor of pida, we observed
that one glycinato donor of the two available in mida achieves in-plane coordination to RuCI(NO)
and one coordinates axially with the amine donor cis to NO [7]. The observed AB pattern with H
4.71 and Ha 4.04 is similar to the in-plane values of H 4.68 and Ha 4.40 whereas axial
coordination of a glycinato methylene has resonances at H 4.31 and Ha 3.89, less downfield
than for the in-plane glycinato chelation. Alteration of synthetic conditions, kinetic influences, and
the orientational placement of donor groups along the synthetic pathways appear to be crucial in
establishing {Ru(NO)}e bonds to carboxylate donors because both are coordinated in the major
isomer (64%), and the least abundant isomer (1%), but not the second most abundant isomer (36%).
For synthetic purposes, a correct choice of conditions might favor a unique distribution. But finding
such a system was not a goal of the present work. Rather, it is deemed of greater value to determine
what kind of ligand sets make stable carriers for the {Ru(NO)}
6 chromophore. Simple monodentate
imidazole donors are insufficient to produce non-labile complexes [7]. Chelation at least as extensive
as bidentate N donors (as in dpaH) is essential for non-lability, and the potentially tridentate midaz
ligand is also too labile. Inclusion of a second N donor as in pida yields a stable system for
RuCla(NO)-based complexes.The neutral complex such as the pida complex in (5) may be useful as
a transporter molecule to get "caged NO across cell walls. Further work in this regard, and the
photo-reactivity studies of these materials are in progress.
Since tumor cells are known to concentrate ruthenium chloro, ammine, and
polyaminopolycarboxylate complexes [23 -26], and the RuCI(NO) chromophore is related as a
simple chloro ruthenium complex to the imidazolium salt, [imH]{trans-[RuCI4(im)]} in use against
colorectal and solid tumors [27 -30], the advances herein contribute to the possible antitumor
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therapies for a number of tumor cell lines. The complexation of the RuCI3(NO) core by
aminocarboxylate donors as reported previously [6 8] and in the present manuscript are of value in
the design of peptide-transportable antitumor agents. The advantage for those derived from (1)
resides in their control against redox side reactions during the transport phase and the possibility of
"turning them on" by selective photolysis, once the species is absorbed by the intended tumor.
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